| Schedule of non-controlling interests in consolidated entities |
Non-controlling interests in consolidated entities are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the nine months ended |
|
|
|
|
|
|
|
|
As of September 30, 2020 |
|
September 30, 2020 |
|
As of September 30, 2020 |
|
|
|
|
|
|
|
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
NCI equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
Aevitas |
|
$ |
(2,297) |
|
|
(680) |
|
|
(2,977) |
|
39.0 |
% |
Avenue 2 |
|
|
5,709 |
|
|
(3,206) |
|
|
2,503 |
|
77.4 |
% |
Baergic |
|
|
(1,605) |
|
|
(68) |
|
|
(1,673) |
|
40.0 |
% |
Cellvation |
|
|
(1,072) |
|
|
(145) |
|
|
(1,217) |
|
22.6 |
% |
Checkpoint 1 |
|
|
37,963 |
|
|
(9,000) |
|
|
28,963 |
|
80.0 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
784 |
|
|
(843) |
|
|
(59) |
|
28.4 |
% |
Helocyte |
|
|
(4,890) |
|
|
(236) |
|
|
(5,126) |
|
18.8 |
% |
JMC |
|
|
123 |
|
|
257 |
|
|
380 |
|
6.9 |
% |
Mustang 2 |
|
|
86,572 |
|
|
(27,035) |
|
|
59,537 |
|
77.9 |
% |
Oncogenuity |
|
|
(47) |
|
|
(268) |
|
|
(315) |
|
25.3 |
% |
Tamid |
|
|
(652) |
|
|
(40) |
|
|
(692) |
|
22.8 |
% |
Total |
|
$ |
120,298 |
|
$ |
(41,264) |
|
$ |
79,034 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the twelve months ended |
|
|
|
|
|
|
|
|
As of December 31, 2019 |
|
December 31, 2019 |
|
As of December 31, 2019 |
|
|
|
|
|
|
|
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
NCI equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
Aevitas |
|
$ |
(1,249) |
|
$ |
(694) |
|
$ |
(1,943) |
|
35.8 |
% |
Avenue 2 |
|
|
24,269 |
|
|
(19,011) |
|
|
5,258 |
|
77.3 |
% |
Baergic |
|
|
23 |
|
|
(1,162) |
|
|
(1,139) |
|
33.0 |
% |
Cellvation |
|
|
(732) |
|
|
(158) |
|
|
(890) |
|
20.6 |
% |
Checkpoint 1 |
|
|
29,389 |
|
|
(14,687) |
|
|
14,702 |
|
78.0 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
(320) |
|
|
(99) |
|
|
(419) |
|
10.6 |
% |
Helocyte |
|
|
(4,322) |
|
|
(402) |
|
|
(4,724) |
|
19.3 |
% |
JMC |
|
|
(211) |
|
|
325 |
|
|
114 |
|
6.9 |
% |
Mustang 2 |
|
|
62,025 |
|
|
(25,727) |
|
|
36,298 |
|
70.3 |
% |
Tamid |
|
|
(565) |
|
|
(85) |
|
|
(650) |
|
22.8 |
% |
Total |
|
$ |
108,017 |
|
$ |
(61,700) |
|
$ |
46,317 |
|
|
|
Note 1: |
Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. |
Note 2: |
Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights. |
|